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Objectives: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate com-
prised of the microtubule inhibitory cytotoxic agent DM1 and trastuzumab which, in 
addition to its antitumor properties, targets T-DM1 to HER2–overexpressing cells. The 
overall safety profile of T-DM1 was investigated in the phase III EMILIA trial (com-
paring T-DM1 [n= 496] to capecitabine plus lapatinib [CAP+LAP, n= 495]) in patients 
with HER2-positive locally advanced or metastatic breast cancer (MBC) previously 
treated with trastuzumab and a taxane, and the phase II TDM4450g trial (comparing 
T-DM1 [n= 67] to trastuzumab plus docetaxel [TRAZ+DOCE, n= 70]) in patients with 
previously untreated MBC. Both trials demonstrated clinically meaningful differ-
ences between T-DM1 and its comparators. The objectives were to estimate and 
compare the Canadian costs of managing the treatment-related adverse events 
(AEs) of T-DM1 as reported in the two trials, from the perspective of Canadian 
public payers. MethOds: An Excel based spreadsheet model was utilized for the 
analysis. Costing information was obtained from the literature, clinical experts, and 
Canadian standard costing sources. Costs were reported as 2012 CAD. The AEs that 
were considered were all treatment-related grade ≥ 3 AEs as well as grade 2 AEs that 
occurred in ≥ 5% of patients in both arms of either study. Results: The manage-
ment of treatment-related AEs as reported in the EMILIA trial resulted in higher per 
patient costs ranging from $3,060 - $10,499 for CAP+LAP versus $1,376 - $2,463 for 
T-DM1, yielding savings of $1,684-$8,036. In the TDM4450g trial, the management 
of treatment-related AEs resulted in higher per patient costs ranging from $5,124 
- $27,617 for TRAZ+DOCE versus $798 - $2,215 for T-DM1, yielding savings of $4,326-
$25,402. cOnclusiOns: This analysis demonstrated that utilizing T-DM1 for the 
management of HER2-positive metastatic breast cancer results in significant cost 
savings of related AEs management due to the improved safety profile compared 
to CAP+LAP and TRAZ+DOCE.
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Objectives: Stereotactic radiation therapy is an innovative technique with high 
therapeutic potential due to excellent local control and increased survival rate. A 
cost analysis investigating stereotactic radiation therapy modalities either with lin-
ear accelerator (Cone Beam Computed Tomography (CBCT), Exac-trac) or Cyberknife 
was conducted. MethOds: The cost-analysis was performed prospectively based 
on a multicenter study. Patients included were treated for lung carcinoma (T1-T2, N0, 
M0). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Only direct costs were taken into account. Productivity 
losses of personnel involved in the process, costs of administrative personnel, costs 
of logistics and general management were not taken into account. Time horizon 
included radiation therapy (preparation for radiation therapy and the fraction itself). 
All costs were given in 2011 euros. Uncertainty was captured by one-way and proba-
bilistic sensitivity analyses using a non-parametric bootstrap method. Results: 
113 patients were enrolled in 11 French centers from April 2009 to December 2011. 
98 economic questionnaires were exploitable. The costs of preparation for stereo-
tactic radiation therapy were 430€ (SD: 101€ ) with Cyberknife and 433€ (SD: 199€ ) 
with linear accelerator. When required, costs of implementation of fiducial markers 
with one/two days of inpatient care were 1,619€ . The costs of stereotactic radia-
tion therapy (all fractions included) were 1,811€ (SD: 760€ ) with Cyberknife and 
817€ (SD:403€ ) with linear accelerator. Costs per fraction were 550€ (SD: 224€ ) with 
Cyberknife and 201€ (SD: 97€ ) with linear accelerator. Depreciation periods of the 
accelerator played a major role in costs. cOnclusiOns: This is to our knowledge 
the first study highlighting costs incurred by different stereotactic radiation therapy 
modalities in lung cancers. Cost-effectiveness studies have to be conducted in order 
to shed further light on which modality to focus on.
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Objectives: Everolimus plus exemestane (EVE+EXE) recently received approval for 
the treatment of patients with HR+/HER2- advanced breast cancer that recurs or 
progresses during/after non-steroidal aromatase inhibitors. This study was designed 
to evaluate the expected costs of managing adverse events during EVE+EXE therapy 
and single-agent chemotherapy in the western European region. MethOds: An 
economic model was developed to estimate per-patient cost of managing adverse 
events for patients receiving EVE+EXE or chemotherapies. Adverse event rates for 
EVE+EXE were collected from the phase III BOLERO-2 trial. Adverse event rates for 
capecitabine, docetaxel, and doxorubicin chemotherapies were collected from 
published clinical trial data. Grade 3/4 adverse events with at least 2% prevalence 
during any of these treatments were included in the study. The adverse event rate 
direct cell death compared with rituximab (Rtx) and is pending regulatory approval 
(in combination with chlorambucil (Clb)) for the treatment of patients with pre-
viously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has 
shown > 85% reduction in the risk of progression, relapse or death in comparison 
to treatment with Clb alone (HR 0.14), a broadly accepted treatment option for many 
patients with co-existing medical conditions. In a majority of markets the health 
economic consequences will be assessed in terms of affordability. MethOds: A 
health economic model was developed analyzing the cost impact of obinutuzumab 
on further lines of treatment due to the number of reduced refractory patients com-
pared to Clb and Rtx. Market share information for obinutuzumab, ofatumumab, 
Rtx, Clb and Bendamustine and the different relevant combinations were entered 
for Germany and Canada (Ontario province only). Results: Based on a 39% reduc-
tion in numbers of refractory patients treated with obinutuzumab+Clb compared 
to Rtx+Clb cost savings per year per patient (PYPP) for further line treatments in 
Canada (Ontario) range between Ca$950 and Ca$3,091, which leads to maximum 
cost savings for the whole eligible population (401 patients) up to $Ca1,239,491. 
In Germany the cost savings range PYPP between € 2,556 and € 8,318, which leads 
to maximum cost savings for the whole eligible population (1,302 patients) up to 
€ 10,830,036. The big difference in the cost savings PYPP between the two coun-
tries is mainly due to the different market share assumptions for ofatumumab. 
Key cost drivers were treatment duration and price/cost of further line treatments. 
Scenario analyses on cost, efficacy and market share data confirmed these find-
ings. cOnclusiOns: Obinutuzumab+Clb shows significant patient-relevant clini-
cal benefits and potential cost savings in further line treatments in patients with 
previously untreated CLL.
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Objectives: To assess the cost-effectiveness of the new transdermal therapeutic sys-
tem (TTS) of fentanyl and subcutaneous injections (SIs) of morphine hydrochloride in 
the treatment of chronic pain and predict potential budget impact of the implementa-
tion of fentanyl TTS in routine clinical practice. MethOds: The pharmacoeconomic 
model was developed based on the results of Russian observational study, included 
45 patients with terminal cancer: 25 patients received fentanyl TTS and 20 – SIs of 
morphine. At the first stage, the cost-effectiveness ratios (CERs) of therapies during 
the first month was measured as total costs of medicines and expenses for ambulance 
services for acute pain relief per one patient without side-effects. At the second stage, 
the CERs of therapies during subsequent three months was measured as costs of 
medicines per one unit of pain intensity (PI) reduction (visual pain scale). Results: 
During the first month of therapy the frequency of ambulance use was significantly 
lower in patients received fentanyl TTS (0.32 vs 1.05 per one patient per week in the 
morphine group), this was reflected in lower total costs (12 611, 42 RUB and 23,037.54 
RUB per one patient, respectively). Patients in the fentanyl TTS group were less likely 
to have side effects. The estimated CERs for fentanyl TTS and SIs of morphine were 
13,001.46 RUB and 27,756.07 RUB per one patient without vomiting and 23,354.47 
RUB and 82,276.93 RUB per one patient without constipation, respectively. Long-term 
treatment with fentanyl TTS was resulted in decreased PI as compared to SIs of mor-
phine. The three-month CERs were 4,897.05 RUB and 7,869.30 RUB per one unit of PI 
reduction, respectively. cOnclusiOns: The present study has demonstrated that 
administration of new transdermal therapeutic system of fentanyl has the better 
cost-effectiveness profile in the treatment of Russian cancer patients.
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Objectives: Chemotherapy-induced neutropenia (CIN), a commonly-occurring 
adverse event in cancer patients undergoing chemotherapy, and particularly febrile 
neutropenia (FN), have potentially life-threatening and costly consequences. The 
standard of care for patients at risk of FN comprises prophylactic administra-
tion of recombinant granulocyte colony-stimulating factor (G-CSF) with pegfil-
grastim, a long-acting formulation of G-CSF, and the most widely used in Europe. 
Lipegfilgrastim is a novel, pegylated and glycosylated long-acting G-CSF designed 
for use in the same patient population as pegfilgrastim. We developed a model to 
estimate the economic impact over five years of managing G-CSF-eligible chem-
otherapy patients at risk of FN with lipegfilgrastim rather than pegfilgrastim in 
Scotland. MethOds: The eligible patient population was estimated based on cancer 
incidence in Scotland and current uptake of G-CSF by patients initiating chemo-
therapy to prevent neutropenia. Drug, monitoring and event costs were taken from 
the British National Formulary, Unit Costs of Health and Social Care and Scottish 
National Tariff. As lipegfilgrastim was shown to be non-inferior to pegfilgrastim (in 
a phase III study in breast cancer patients), the efficacy and safety of pegfilgrastim 
and lipegfilgrastim were assumed to be identical. Non-statistically significant trends 
towards fewer neutropenic events and dose modifications with lipegfilgrastim were 
explored in scenario analyses. Results: The model estimated that 315 patients 
currently receive pegfilgrastim annually. A progressive increase in lipegfilgrastim 
uptake was associated with cost savings ranging from £2,814 in year 1 to £16,883 in 
year 5, totalling £61,904 over five years. Savings were attributable to the low drug 
acquisition cost of lipegfilgrastim. Using event rates from the pivotal phase III breast 
cancer study, scenario analyses suggested that using lipegfilgrastim instead of peg-
filgrastim generated savings of £145,312, avoided 81 neutropenic events (including 
11 occurrences of FN) and 50 dose modifications, and caused 34 additional treat-
ment-emergent adverse events. cOnclusiOns: Lipegfilgrastim was cost-saving 
compared with pegfilgrastim.
